Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

ments."

"VTX-2337 provides unique abilities compared to other TLR agonists in clinical development, most notably a robust and highly selective activation of myeloid dendritic cells and natural killer cells," said Robert Hershberg, M.D., Ph.D., President and Chief Medical Officer of VentiRx. "These preclinical efficacy findings combined with the favorable safety profile of VTX-2337 established in the recently completed Phase 1 trial support the advancement of our broad clinical development program currently underway to evaluate the safety and efficacy of VTX-2337 in combination with standard of care cancer therapies."

VentiRx has advanced VTX-2337 into clinical trials designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy and monoclonal antibody therapy. Clinical trials of VTX-2337 currently underway include a combination study with chemotherapy in late stage ovarian cancer and a combination trial with cetuximab in head and neck cancer patients. In addition, a trial of VTX-2337 in combination with chemotherapy in metastatic breast cancer is targeted to begin in mid-2012.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The Company's initial focus is on developing novel small molecule product candidates targeting Toll-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in Seattle. For additional information, please visit www.ventirx.com.

 

Contact:

Robert Hershberg, M.D., Ph.D.
President and Chief Medical Officer
VentiRx Pharmaceuticals, Inc.
(206) 689-2268
rhershberg@ventirx.com

Julie Rathbun

'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RPh, of Vernak Farms Pharmacy in Skaneateles, ... Roentsch Scholarship by the Professional Compounding Centers of America ... during PCCA,s International Seminar, held October 8-10, ... pharmacist and PCCA member who embodies the innovative and ... pharmacist in the compounding community. George ...
(Date:10/22/2014)... 2014 A new report by ... type, Form, End user, Application and Geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", considers ... on key trends tracked, it is anticipated that the ... by 2020, registering a CAGR of 6.2% from 2014 ...
(Date:10/22/2014)... LOUIS , Oct. 21, 2014  Early ... often subtle or unnoticed, but new technology, coupled ... outcomes and leading to earlier detection of eye ... affects 29 million Americans. If left untreated, these ... even blindness. Recently, optometric researchers ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
(Date:10/22/2014)... October 22, 2014 Isabel Healthcare ... Allied Health Professions (ASAHP) Conference on October 22-24 in ... will participate in a panel discussion on Technology in ... Isabel Healthcare provides a diagnostic decision support tool and ... diagnosis skills of students and clinical learners. The Isabel ...
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare ... location of Shriners Hospitals for Children - Lexington from ... University of Kentucky Albert B. Chandler Hospital. The new ... and operated by Shriners Hospitals for Children, and designed ... their families well into the future. , “The quality ...
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... and disabling a protein frequently found in melanoma tumors, ... vulnerable to chemotherapy, according to early results of a ... Cancer Center. , "In this pilot study, we gave ... been shown in pre-clinical studies to weaken melanoma tumors ...
... ALOKA Co., Ltd. will be unveiling a new ... - ECR2009 - to be held from March 6th, ... for ultrasound systems with higher cost-effectiveness, flexibility, ease of ... stand-alone, black-and-white system with the latest digital technologies engineered ...
... nurse and allied professional are already at the heart ... and Professor Christi Deaton, Chairperson of the ESC Council ... even greater role given the complex needs of people ... prevent cardiovascular disease," says Professor Deaton, "and we have ...
... MIAMI, March 6 Eight projects in the Miami-Dade ... for projects focused on addressing transportation and mobility options ... for all. The winning projects were chosen based on ... counties, "Aging in Place" services.The grants were the result ...
... Important information on display at 10 Rockefeller Plaza through ... the month of March, the Alzheimer,s Association, New York ... Chapter services. This is due to the generosity ... construct a 115-square foot display in its window at ...
... stores, studies find , , FRIDAY, March 6 (HealthDay News) ... are much less likely to offer healthy foods than ... live matters in terms of your diet," said study ... Hopkins Bloomberg School of Public Health in Baltimore. "If ...
Cached Medicine News:Health News:Drug combination may be effective against deadly melanoma, pilot study shows 2Health News:ALOKA Showcases a New Diagnostic Ultrasound System ProSound 4 at ECR 2009 in Vienna, Austria 2Health News:Nurses and allied professionals at heart of cardiovascular prevention and management programs 2Health News:Nurses and allied professionals at heart of cardiovascular prevention and management programs 3Health News:Miami-Dade and Monroe County Organizations Receive Grants to 'JumpStart the Conversation' 2Health News:Miami-Dade and Monroe County Organizations Receive Grants to 'JumpStart the Conversation' 3Health News:Miami-Dade and Monroe County Organizations Receive Grants to 'JumpStart the Conversation' 4Health News:EHE International Helps Alzheimer's Association, New York City Chapter to Raise Awareness About Alzheimer's Disease 2Health News:Healthy Foods Harder to Find in Poor Neighborhoods 2Health News:Healthy Foods Harder to Find in Poor Neighborhoods 3Health News:Healthy Foods Harder to Find in Poor Neighborhoods 4
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: